Publications

Filters: First Letter Of Keyword is D and Author is Zeng, Donglin  [Clear All Filters]
Journal Article
Cai, Jianwen, and Donglin Zeng. "Additive mixed effect model for clustered failure time data." Biometrics 67, no. 4 (2011): 1340-51.
Cai, Jianwen, and Donglin Zeng. "Additive mixed effect model for clustered failure time data." Biometrics 67, no. 4 (2011): 1340-51.
Zeng, Donglin, Emil Cornea, Jun Dong, Jean Pan, and Joseph G. Ibrahim. "Assessing temporal agreement between central and local progression-free survival times." Stat Med 34, no. 5 (2015): 844-58.
Zeng, Donglin, Emil Cornea, Jun Dong, Jean Pan, and Joseph G. Ibrahim. "Assessing temporal agreement between central and local progression-free survival times." Stat Med 34, no. 5 (2015): 844-58.
Liu, Ying, Yuanjia Wang, Michael R. Kosorok, Yingqi Zhao, and Donglin Zeng. "Augmented outcome-weighted learning for estimating optimal dynamic treatment regimens." Stat Med 37, no. 26 (2018): 3776-3788.
Chen, Ming-Hui, Joseph G. Ibrahim, Donglin Zeng, Kuolung Hu, and Catherine Jia. "Bayesian design of superiority clinical trials for recurrent events data with applications to bleeding and transfusion events in myelodyplastic syndrome." Biometrics 70, no. 4 (2014): 1003-13.
Zhang, Yuanye, Ming-Hui Chen, Joseph G. Ibrahim, Donglin Zeng, Qingxia Chen, Zhiying Pan, and Xiaodong Xue. "Bayesian gamma frailty models for survival data with semi-competing risks and treatment switching." Lifetime Data Anal 20, no. 1 (2014): 76-105.
Diao, Guoqing, Jun Dong, Donglin Zeng, Chunlei Ke, Alan Rong, and Joseph G. Ibrahim. "Biomarker threshold adaptive designs for survival endpoints." J Biopharm Stat 28, no. 6 (2018): 1038-1054.
Zeng, Donglin, Ming-Hui Chen, Joseph G. Ibrahim, Rachel Wei, Beiying Ding, Chunlei Ke, and Qi Jiang. "A counterfactual p-value approach for benefit-risk assessment in clinical trials." J Biopharm Stat 25, no. 3 (2015): 508-24.
Zeng, Donglin, Ming-Hui Chen, Joseph G. Ibrahim, Rachel Wei, Beiying Ding, Chunlei Ke, and Qi Jiang. "A counterfactual p-value approach for benefit-risk assessment in clinical trials." J Biopharm Stat 25, no. 3 (2015): 508-24.
Diao, Guoqing, Guanghan F. Liu, Donglin Zeng, William Wang, Xianming Tan, Joseph F. Heyse, and Joseph G. Ibrahim. "Efficient methods for signal detection from correlated adverse events in clinical trials." Biometrics 75, no. 3 (2019): 1000-1008.
Diao, Guoqing, Donglin Zeng, and Song Yang. "Efficient semiparametric estimation of short-term and long-term hazard ratios with right-censored data." Biometrics 69, no. 4 (2013): 840-9.
Liu, Ying, Yuanjia Wang, Chaorui Huang, and Donglin Zeng. "Estimating personalized diagnostic rules depending on individualized characteristics." Stat Med 36, no. 7 (2017): 1099-1117.
Liu, Ying, Yuanjia Wang, Chaorui Huang, and Donglin Zeng. "Estimating personalized diagnostic rules depending on individualized characteristics." Stat Med 36, no. 7 (2017): 1099-1117.
Liu, Ying, Yuanjia Wang, Chaorui Huang, and Donglin Zeng. "Estimating personalized diagnostic rules depending on individualized characteristics." Stat Med 36, no. 7 (2017): 1099-1117.
Lin, Dan-Yu, Donglin Zeng, and David Couper. "A general framework for integrative analysis of incomplete multiomics data." Genet Epidemiol 44, no. 7 (2020): 646-664.
Chen, Tianle, Donglin Zeng, and Yuanjia Wang. "Multiple kernel learning with random effects for predicting longitudinal outcomes and data integration." Biometrics 71, no. 4 (2015): 918-28.
Zeng, Donglin, Joseph G. Ibrahim, Ming-Hui Chen, Kuolung Hu, and Catherine Jia. "Multivariate recurrent events in the presence of multivariate informative censoring with applications to bleeding and transfusion events in myelodysplastic syndrome." J Biopharm Stat 24, no. 2 (2014): 429-42.
Chen, Huaihou, Donglin Zeng, and Yuanjia Wang. "Penalized nonlinear mixed effects model to identify biomarkers that predict disease progression." Biometrics 73, no. 4 (2017): 1343-1354.
Chen, Qingxia, Donglin Zeng, Joseph G. Ibrahim, Ming-Hui Chen, Zhiying Pan, and Xiaodong Xue. "Quantifying the average of the time-varying hazard ratio via a class of transformations." Lifetime Data Anal 21, no. 2 (2015): 259-79.
Zhao, Yufan, Donglin Zeng, Mark A. Socinski, and Michael R. Kosorok. "Reinforcement learning strategies for clinical trials in nonsmall cell lung cancer." Biometrics 67, no. 4 (2011): 1422-33.
Zhao, Yufan, Donglin Zeng, Mark A. Socinski, and Michael R. Kosorok. "Reinforcement learning strategies for clinical trials in nonsmall cell lung cancer." Biometrics 67, no. 4 (2011): 1422-33.
Gao, Fei, Donglin Zeng, and Dan-Yu Lin. "Semiparametric regression analysis of interval-censored data with informative dropout." Biometrics 74, no. 4 (2018): 1213-1222.
Diao, Guoqing, Donglin Zeng, Joseph G. Ibrahim, Alan Rong, Oliver Lee, Kathy Zhang, and Qingxia Chen. "Statistical design of noninferiority multiple region clinical trials to assess global and consistent treatment effects." J Biopharm Stat 27, no. 6 (2017): 933-944.
Laber, Eric B., Ying-Qi Zhao, Todd Regh, Marie Davidian, Anastasios Tsiatis, Joseph B. Stanford, Donglin Zeng, Rui Song, and Michael R. Kosorok. "Using pilot data to size a two-arm randomized trial to find a nearly optimal personalized treatment strategy." Stat Med 35, no. 8 (2016): 1245-56.
Lu, Wenbin, Hao Helen Zhang, and Donglin Zeng. "Variable selection for optimal treatment decision." Stat Methods Med Res 22, no. 5 (2013): 493-504.